Suppr超能文献

银屑病表皮中血浆激肽释放酶和组织激肽释放酶的部分纯化

Partial purification of plasma and tissue kallikreins in psoriatic epidermis.

作者信息

Hibino T, Izaki S, Kimura H, Izaki M, Kon S

机构信息

Department of Dermatology, Iwate Medical University School of Medicine, Morioka, Japan.

出版信息

J Invest Dermatol. 1988 Apr;90(4):505-10. doi: 10.1111/1523-1747.ep12460988.

Abstract

Human psoriatic scale extracts produced kinins from heated plasma (11.3 +/- 5.5 ng kinin/mg protein) and from purified low molecular weight (LMW) bovine kininogen (4.4 +/- 1.7 ng/mg). Sephacryl S-200 gel filtration of the extracts showed three peaks of kininogenase activity with Mr values of 90,000 (K-I), 65,000 (K-II), and 35,000 (K-III). Upon DEAE-Sepharose chromatography of the Sephacryl peaks, K-I activity was found in the nonadsorbed fraction and formed kinins only from heated plasma. Peak K-II activity was resolved into two peaks, K-IIa (in the nonadsorbed fraction), which formed kinins only from heated plasma, and K-IIb (in the adsorbed fraction), which formed kinins from both heated plasma and LMW bovine kininogen. K-III kininogenase activity appeared at the same position as K-IIb and also formed kinins from both substrates. Kininogenases K-I and K-IIa had the same Km value (0.3 mM) with Pro-Phe-Arg-p-nitroanilide(pNA), similar to that found with human plasma kallikrein. The Km value of K-IIb with Val-Leu-Arg-pNA (0.8 mM) was like that found for human salivary kallikrein, whereas K-III had a low affinity for this substrate. Like plasma kallikrein, K-I and K-IIa were inhibited by soybean trypsin inhibitor, but only weakly by aprotinin. In addition the kininogenase activity of both K-I and K-IIa was neutralized by adding antihuman prekallikrein immunoglobulin G (IgG). In contrast, K-IIb and K-III were strongly inhibited by aprotinin but not by soybean trypsin inhibitor, consistent with their being tissue kallikreins. It was confirmed that K-IIb and K-III shares antigenic determinant of urinary kallikrein.

摘要

人银屑病鳞屑提取物可从加热血浆(11.3±5.5 ng激肽/毫克蛋白质)和纯化的低分子量(LMW)牛激肽原(4.4±1.7 ng/毫克)中产生激肽。提取物经Sephacryl S - 200凝胶过滤显示出三个激肽原酶活性峰,其分子量(Mr)值分别为90,000(K - I)、65,000(K - II)和35,000(K - III)。对Sephacryl峰进行DEAE - Sepharose层析时,K - I活性存在于未吸附部分,且仅从加热血浆中形成激肽。K - II活性峰可分为两个峰,K - IIa(在未吸附部分),仅从加热血浆中形成激肽;K - IIb(在吸附部分),可从加热血浆和LMW牛激肽原中形成激肽。K - III激肽原酶活性出现在与K - IIb相同的位置,也可从两种底物中形成激肽。激肽原酶K - I和K - IIa对Pro - Phe - Arg - p - 硝基苯胺(pNA)的Km值相同(0.3 mM),与人血浆激肽释放酶的Km值相似。K - IIb对Val - Leu - Arg - pNA的Km值(0.8 mM)与人唾液激肽释放酶的Km值相似,而K - III对该底物的亲和力较低。与血浆激肽释放酶一样,K - I和K - IIa被大豆胰蛋白酶抑制剂抑制,但被抑肽酶抑制较弱。此外,加入抗人前激肽释放酶免疫球蛋白G(IgG)可中和K - I和K - IIa的激肽原酶活性。相反,K - IIb和K - III被抑肽酶强烈抑制,但不被大豆胰蛋白酶抑制剂抑制,这与其作为组织激肽释放酶一致。已证实K - IIb和K - III具有尿激肽释放酶的抗原决定簇。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验